Skip to main content
Top
Published in: Calcified Tissue International 4/2004

01-04-2004

Treatment with Parathyroid Hormone hPTH(1-34), hPTH(1-31), and Monocyclic hPTH(1-31) Enhances Fracture Strength and Callus Amount After Withdrawal Fracture Strength and Callus Mechanical Quality Continue to Increase

Authors: T. T. Andreassen, G. E. Willick, P. Morley, J. F. Whitfield

Published in: Calcified Tissue International | Issue 4/2004

Login to get access

Abstract

The influence of intermittent hPTH(l-34)NH2, hPTH(1-31)NH2, and monocyclic [Leu27]cyclo(Glu22-Lys26)hPTH(1-31)NH2 treatment on callus formation, mechanical strength, and callus tissue mechanical quality of tibial fractures in rats was investigated after 8 and 16 weeks of healing. In the 8 weeks of healing animals, the PTH-peptides were injected subcutaneously during the entire observation period (15 nmol/kg/day [hPTH(1-34)NH2: 15 nmol = 60 µg]), and control animals with fractures were given vehicle. In the 16 weeks of healing animals, the PTH-peptides were injected only during the first 8 weeks of healing (15 nmol/kg/day), after which the animals were left untreated during the rest of the healing period. After the first 8 weeks of healing, increased fracture strength and callus volume were seen in the PTH-treated rats (ultimate load 66%, ultimate stiffness 58%, callus volume 28%), and the three peptides were equally effective. No difference in callus tissue mechanical quality was found between PTH and vehicle animals. After 16 weeks of healing, no differences in fracture strength, callus volume, or callus tissue mechanical quality were seen between PTH and vehicle. When comparing PTH-treated animals at 8 and 16 weeks, fracture strength and callus tissue mechanical quality continued to increase after the withdrawal of PTH (ultimate load 23%, ultimate stress 88%, elastic modulus 87%) and external callus volume declined during this period (27%).
Literature
1.
go back to reference Shen, V, Dempster, DW, Mellish, RWE, Birchman, R, Horbert, W, Lindsay, R 1992Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1–34) and 17β-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia.Calcif Tissue Int50214220PubMed Shen, V, Dempster, DW, Mellish, RWE, Birchman, R, Horbert, W, Lindsay, R 1992Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1–34) and 17β-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia.Calcif Tissue Int50214220PubMed
2.
go back to reference Oxlund, H, Ejersted, C, Andreassen, TT, Tørring, O, Nilsson, MHL 1993Parathyroid hormone (1–34) and (1–84) stimulate cortical bone formation both from periosteum and endosteum.Calcif Tissue Int53394399 Oxlund, H, Ejersted, C, Andreassen, TT, Tørring, O, Nilsson, MHL 1993Parathyroid hormone (1–34) and (1–84) stimulate cortical bone formation both from periosteum and endosteum.Calcif Tissue Int53394399
3.
go back to reference Wronski, TJ, Yen, C-F, Qi, H, Dann, LM 1993Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats.Endocrinology132823831 Wronski, TJ, Yen, C-F, Qi, H, Dann, LM 1993Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats.Endocrinology132823831
4.
go back to reference Mosekilde, L, Danielsen, CC, Gasser, J 1994The effect on vertebral bone mass and strength of long-term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats.Endocrinology13421262134 Mosekilde, L, Danielsen, CC, Gasser, J 1994The effect on vertebral bone mass and strength of long-term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats.Endocrinology13421262134
5.
go back to reference Ejersted, C, Andreassen, TT, Nilsson, MHL, Oxlund, H 1994Human parathyroid hormone (1–34) increases bone formation and strength of cortical bone in aged rats.Eur J Endocrinol130201207 Ejersted, C, Andreassen, TT, Nilsson, MHL, Oxlund, H 1994Human parathyroid hormone (1–34) increases bone formation and strength of cortical bone in aged rats.Eur J Endocrinol130201207
6.
go back to reference Mosekilde, L, Danielsen, CC, Søgaard, CH, McOsker, JE, Wronski, TJ 1995The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength - assessed in a sexually mature, ovariectomized rat model.Bone16223230CrossRefPubMed Mosekilde, L, Danielsen, CC, Søgaard, CH, McOsker, JE, Wronski, TJ 1995The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength - assessed in a sexually mature, ovariectomized rat model.Bone16223230CrossRefPubMed
7.
go back to reference Dobnig, H, Turner, RT 1995Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells.Endocrinology13636323638 Dobnig, H, Turner, RT 1995Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells.Endocrinology13636323638
8.
go back to reference Whitfield, JF, Morley, P, Willick, G, Maclean, S, Ross, V, Isaacs, RJ, Barbier, J-R 1998Comparison of the abilities of human parathyroid hormone (hPTH)-(1-34) and [Leu27]-cyclo(Glu22-Lys26)-hPTH-(1-31)NH2 to stimulate femoral trabecular bone growth in ovariectomized rats.Calcif Tissue Int63423428CrossRefPubMed Whitfield, JF, Morley, P, Willick, G, Maclean, S, Ross, V, Isaacs, RJ, Barbier, J-R 1998Comparison of the abilities of human parathyroid hormone (hPTH)-(1-34) and [Leu27]-cyclo(Glu22-Lys26)-hPTH-(1-31)NH2 to stimulate femoral trabecular bone growth in ovariectomized rats.Calcif Tissue Int63423428CrossRefPubMed
9.
go back to reference Andreassen, TT, Oxlund, H 2000The influence of combined parathyroid hormone and growth hormone treatment on cortical bone in aged ovariectomized rats.J Bone Miner Res1522662275 Andreassen, TT, Oxlund, H 2000The influence of combined parathyroid hormone and growth hormone treatment on cortical bone in aged ovariectomized rats.J Bone Miner Res1522662275
10.
go back to reference Ejersted, C, Andreassen, TT, Oxlund, H, Jørgensen, PH, Bak, B, Häggblad, J, Tørring, O, Nilsson, MHL 1993Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats.J Bone Miner Res810971101PubMed Ejersted, C, Andreassen, TT, Oxlund, H, Jørgensen, PH, Bak, B, Häggblad, J, Tørring, O, Nilsson, MHL 1993Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats.J Bone Miner Res810971101PubMed
11.
go back to reference Sato, M, Zeng, GQ, Turner, CH 1997Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats.Endocrinology13843304337PubMed Sato, M, Zeng, GQ, Turner, CH 1997Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats.Endocrinology13843304337PubMed
12.
go back to reference Ejersted, C, Oxlund, H, Eriksen, EF, Andreassen, TT 1998Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats.Bone234352CrossRefPubMed Ejersted, C, Oxlund, H, Eriksen, EF, Andreassen, TT 1998Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats.Bone234352CrossRefPubMed
13.
go back to reference Shen, V, Birchman, R, Liang, XG, Wu, DD, Dempster, DW, Lindsay, R 1998Accretion of bone mass and strength with parathyroid hormone prior to the onset of estrogen deficiency can provide temporary beneficial effects in skeletally mature rats.J Bone Miner Res13883890 Shen, V, Birchman, R, Liang, XG, Wu, DD, Dempster, DW, Lindsay, R 1998Accretion of bone mass and strength with parathyroid hormone prior to the onset of estrogen deficiency can provide temporary beneficial effects in skeletally mature rats.J Bone Miner Res13883890
14.
go back to reference Morley, P, Whitfield, JF, Willick, GE, Ross, V, Maclean, S, Barbier, J-R, Isaacs, RJ, Andreassen, TT 2001The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1-31)NH2 on bone formation and mechanical strength in ovariectomized rats.Calcif Tissue Int6895101PubMed Morley, P, Whitfield, JF, Willick, GE, Ross, V, Maclean, S, Barbier, J-R, Isaacs, RJ, Andreassen, TT 2001The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1-31)NH2 on bone formation and mechanical strength in ovariectomized rats.Calcif Tissue Int6895101PubMed
15.
go back to reference Yamamoto, N, Takahashi, HE, Tanizawa, T, Fujimoto, R, Hara, T, Tanaka, S 1993Maintenance of bone mass by physical exercise after discontinuation of intermittent hPTH(1-34) administration.Bone Miner23333342 Yamamoto, N, Takahashi, HE, Tanizawa, T, Fujimoto, R, Hara, T, Tanaka, S 1993Maintenance of bone mass by physical exercise after discontinuation of intermittent hPTH(1-34) administration.Bone Miner23333342
16.
go back to reference Takano, Y, Tanizawa, T, Mashiba, T, Endo, N, Nishida, S, Takahashi, HE 1996Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats.J Bone Miner Res11169177 Takano, Y, Tanizawa, T, Mashiba, T, Endo, N, Nishida, S, Takahashi, HE 1996Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats.J Bone Miner Res11169177
17.
go back to reference Ejersted, C, Oxlund, H, Andreassen, TT 1998Bisphosphonate maintains parathyroid hormone (1-34)-induced cortical bone mass and mechanical competence in old rats.Calcif Tissue Int62316322CrossRefPubMed Ejersted, C, Oxlund, H, Andreassen, TT 1998Bisphosphonate maintains parathyroid hormone (1-34)-induced cortical bone mass and mechanical competence in old rats.Calcif Tissue Int62316322CrossRefPubMed
18.
go back to reference Andreassen, TT, Ejersted, C, Oxlund, H 1999Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures.J Bone Miner Res14960968 Andreassen, TT, Ejersted, C, Oxlund, H 1999Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures.J Bone Miner Res14960968
19.
go back to reference Holzer, G, Majeska, RJ, Lundy, MW, Hartke, JR, Einhorn, TA 1999Parathyroid hormone enhances fracture healing. A preliminary report.Clin Orthop366258263CrossRefPubMed Holzer, G, Majeska, RJ, Lundy, MW, Hartke, JR, Einhorn, TA 1999Parathyroid hormone enhances fracture healing. A preliminary report.Clin Orthop366258263CrossRefPubMed
20.
go back to reference Jahng, JS, Kim, HW 2000Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats.Orthopedics2310891094PubMed Jahng, JS, Kim, HW 2000Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats.Orthopedics2310891094PubMed
21.
go back to reference Andreassen, TT, Fledelius, C, Ejersted, C, Oxlund, H 2001Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone.Acta Orthop Scand72304307CrossRefPubMed Andreassen, TT, Fledelius, C, Ejersted, C, Oxlund, H 2001Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone.Acta Orthop Scand72304307CrossRefPubMed
22.
go back to reference Nakajima, A, Shimoji, N, Shiomi, K, Shimizu, S, Moriya, H, Einhorn, TA, Yamazaki, M 2002Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1–34).J Bone Miner Res1720382047PubMed Nakajima, A, Shimoji, N, Shiomi, K, Shimizu, S, Moriya, H, Einhorn, TA, Yamazaki, M 2002Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1–34).J Bone Miner Res1720382047PubMed
23.
go back to reference Barbier, J-R, Neugebauer, W, Morley, P, Ross, V, Soska, M, Whitfield, JF, Willick, G 1997Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: cyclic lactams of the receptor binding region.J Med Chem4013731380CrossRefPubMed Barbier, J-R, Neugebauer, W, Morley, P, Ross, V, Soska, M, Whitfield, JF, Willick, G 1997Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: cyclic lactams of the receptor binding region.J Med Chem4013731380CrossRefPubMed
24.
go back to reference Turner, CH, Burr, DB 1993Basic biomechanical measurement of bone: a tutorial.Bone14595608PubMed Turner, CH, Burr, DB 1993Basic biomechanical measurement of bone: a tutorial.Bone14595608PubMed
25.
go back to reference Jørgensen, PH, Bak, B, Andreassen, TT 1991Mechanical properties and biochemical composition of rat cortical femur and tibia after long-term treatment with biosynthetic human growth hormone.Bone12353359PubMed Jørgensen, PH, Bak, B, Andreassen, TT 1991Mechanical properties and biochemical composition of rat cortical femur and tibia after long-term treatment with biosynthetic human growth hormone.Bone12353359PubMed
26.
go back to reference Bak, B, Jørgensen, PH, Andreassen, TT 1991The stimulating effect of growth hormone on fracture healing is dependent on onset and duration of administration.Clin Orthop264295301PubMed Bak, B, Jørgensen, PH, Andreassen, TT 1991The stimulating effect of growth hormone on fracture healing is dependent on onset and duration of administration.Clin Orthop264295301PubMed
27.
go back to reference Fraher, LJ, Avram, R, Watson, PH, Hendy, GN, Henderson, JE, Chong, KL, Goltzman, D, Morley, P, Willick, GE, Whitfield, JF, Hodsman, AB 1999Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans.J Clin Endocrinol Metab8427392743PubMed Fraher, LJ, Avram, R, Watson, PH, Hendy, GN, Henderson, JE, Chong, KL, Goltzman, D, Morley, P, Willick, GE, Whitfield, JF, Hodsman, AB 1999Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans.J Clin Endocrinol Metab8427392743PubMed
28.
go back to reference Mohan, S, Kutilek, S, Zhang, C, Shen, HG, Kodama, Y, Srivastava, AK, Wergedal, JE, Beamer, WG, Baylink, DJ 2000Comparison of bone formation responses to parathyroid hormone (1-34), (1-31), and (2-34) in mice.Bone27471478CrossRefPubMed Mohan, S, Kutilek, S, Zhang, C, Shen, HG, Kodama, Y, Srivastava, AK, Wergedal, JE, Beamer, WG, Baylink, DJ 2000Comparison of bone formation responses to parathyroid hormone (1-34), (1-31), and (2-34) in mice.Bone27471478CrossRefPubMed
29.
go back to reference Bostrom, MPG, Gamradt, SC, Asnis, P, Vickery, BH, Hill, E, Avnur, Z, Waters, RV 2000Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy.Bone26437442CrossRefPubMed Bostrom, MPG, Gamradt, SC, Asnis, P, Vickery, BH, Hill, E, Avnur, Z, Waters, RV 2000Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy.Bone26437442CrossRefPubMed
30.
go back to reference Skripitz, R, Andreassen, TT, Aspenberg, P 2000Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber.J Bone Joint Surg Br82-B138141 Skripitz, R, Andreassen, TT, Aspenberg, P 2000Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber.J Bone Joint Surg Br82-B138141
31.
go back to reference Skripitz, R, Andreassen, TT, Aspenberg, P 2000Strong effect of PTH (1-34) on regenerating bone: a time sequence study in rats.Acta Orthop Scand71619624CrossRefPubMed Skripitz, R, Andreassen, TT, Aspenberg, P 2000Strong effect of PTH (1-34) on regenerating bone: a time sequence study in rats.Acta Orthop Scand71619624CrossRefPubMed
32.
go back to reference Skripitz, R, Aspenberg, P 2001Implant fixation enhanced by intermittent treatment with parathyroid hormone.J Bone Joint Surg Br83-B437440CrossRef Skripitz, R, Aspenberg, P 2001Implant fixation enhanced by intermittent treatment with parathyroid hormone.J Bone Joint Surg Br83-B437440CrossRef
33.
go back to reference Skripitz, R, Aspenberg, P 2001Early effect of parathyroid hormone (1-34) on implant fixation.Clin Orthop292427432 Skripitz, R, Aspenberg, P 2001Early effect of parathyroid hormone (1-34) on implant fixation.Clin Orthop292427432
34.
go back to reference Lindsay, R, Nieves, J, Formica, C, Henneman, E, Woelfert, L, Shen, V, Dempster, D, Cosman, F 1997Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.Lancet350550555PubMed Lindsay, R, Nieves, J, Formica, C, Henneman, E, Woelfert, L, Shen, V, Dempster, D, Cosman, F 1997Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.Lancet350550555PubMed
35.
go back to reference Rittmaster, RS, Bolognese, M, Ettinger, MP, Hanley, DA, Hodsman, AB, Kendler, DL, Rosen, CJ 2000Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.J Clin Endocrinol Metab8521292134PubMed Rittmaster, RS, Bolognese, M, Ettinger, MP, Hanley, DA, Hodsman, AB, Kendler, DL, Rosen, CJ 2000Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.J Clin Endocrinol Metab8521292134PubMed
36.
go back to reference Neer, RM, Arnaud, CD, Zanchetta, JR, Prince, R, Gaich, GA, Reginster, J-Y, Hodsman, AB, Eriksen, EF, Ish-Shalom, S, Genant, HK, Wang, O, Mitlak, BH 2001Effect of parathyroid hormone (1-34) on fractures and bone mineral densizty in postmenopausal women with osteoporosis.N Engl J Med34414341441PubMed Neer, RM, Arnaud, CD, Zanchetta, JR, Prince, R, Gaich, GA, Reginster, J-Y, Hodsman, AB, Eriksen, EF, Ish-Shalom, S, Genant, HK, Wang, O, Mitlak, BH 2001Effect of parathyroid hormone (1-34) on fractures and bone mineral densizty in postmenopausal women with osteoporosis.N Engl J Med34414341441PubMed
37.
go back to reference Orwoll, ES, Scheele, WH, Paul, S, Adami, S, Syversen, U, Diez-Perez, A, Kaufman, J-M, Clancy, AD, Gaich, GA 2003The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.J Bone Miner Res18917PubMed Orwoll, ES, Scheele, WH, Paul, S, Adami, S, Syversen, U, Diez-Perez, A, Kaufman, J-M, Clancy, AD, Gaich, GA 2003The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.J Bone Miner Res18917PubMed
38.
go back to reference Marcus, R, Wang, O, Satterwhite, J, Mitlak, B 2003The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.J Bone Miner Res181823PubMed Marcus, R, Wang, O, Satterwhite, J, Mitlak, B 2003The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.J Bone Miner Res181823PubMed
Metadata
Title
Treatment with Parathyroid Hormone hPTH(1-34), hPTH(1-31), and Monocyclic hPTH(1-31) Enhances Fracture Strength and Callus Amount After Withdrawal Fracture Strength and Callus Mechanical Quality Continue to Increase
Authors
T. T. Andreassen
G. E. Willick
P. Morley
J. F. Whitfield
Publication date
01-04-2004
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 4/2004
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-003-0093-6

Other articles of this Issue 4/2004

Calcified Tissue International 4/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.